NASDAQ: TNYA Tenaya Therapeutics, Inc. 10-Q

Tenaya reports first revenue, stronger gene therapy trial data, but cash drops to $81M

Filed May 6, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 7, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade TNYA commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.